R. Pajouheshnia

First name

R.

Last name

Pajouheshnia

Hageman, S. H., Petitjean, C., Pennells, L., Kaptoge, S., Pajouheshnia, R., Tillmann, T., et al. (2023). Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2. Eur J Prev Cardiol. http://doi.org/10.1093/eurjpc/zwad187

View

Hunt, N. B., Pajouheshnia, R., Salih, A., van Doorn, S., Souverein, P. C., Bazelier, M. T., et al. (2023). Prescribing of Low-dose Rivaroxaban in Patients with Atherosclerotic Cardiovascular Disease in the United Kingdom and the Netherlands. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.15708

View

van den Dries, C. J., Pajouheshnia, R., van den Ham, H. A., Souverein, P., Moons, K. G. M., Hoes, A. W., et al. (2022). Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.15534

View

Leung, M. W., Bazelier, M. T., Souverein, P. C., Uitdehaag, B. M., Klungel, O. H., Leufkens, H. G., & Pajouheshnia, R. (2022). Mapping the risk of infections in patients with multiple sclerosis: A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum. Mult Scler, 13524585221094218. http://doi.org/10.1177/13524585221094218

View

van den Dries, C. J., van Doorn, S., Souverein, P., Pajouheshnia, R., Moons, K. G. M., Hoes, A. W., et al. (2020). The Number of Concomitant Drugs and the Safety of Direct Oral Anticoagulants in Routine Care Patients with Atrial Fibrillation. TH Open. http://doi.org/10.1055/s-0040-1721499

View